OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NANEXA56

Nanexa AB

Medical Equipment, Supplies & DistributionVerified

Nanexa AB's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative approach to leverage. However, the company's liquidity position is assessed as medium, with a current ratio of 1.51, suggesting it has sufficient short-term assets to cover its liabilities but with limited buffer for unexpected cash flow disruptions. The company's free cash flow is negative at -23.6 million SEK, and operating cash flow is also negative at -1.5 million SEK, signaling ongoing cash burn despite a net cash position that turns negative after subtracting total debt. Profitability metrics for Nanexa AB are weak, with a return on equity (ROE) of -11.22% and a return on assets (ROA) of -8.24%. These figures are below the typical thresholds for healthy performance in the medical equipment and supplies industry, where ROE and ROA are key indicators of operational efficiency and capital utilization. The company reported a net loss of 11.4 million SEK and an operating loss of 8.8 million SEK, further underscoring the challenges in achieving profitability. The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no material geographic diversification provided in the available data. This lack of segment or geographic diversification increases exposure to sector-specific risks and limits the ability to offset performance shortfalls in one area with gains in another. Nanexa AB's growth trajectory is currently constrained, with no specific revenue growth projections provided in the outlook. The company's capital expenditures of 24.7 million SEK reflect ongoing investment in infrastructure or expansion, but the negative free cash flow suggests these investments are not yet generating sufficient returns. The absence of a clear growth strategy or revenue acceleration in the near term raises concerns about the company's ability to scale profitably. The risk assessment highlights liquidity as a medium concern, with the company's negative free cash flow and operating cash flow indicating a reliance on external financing or asset sales to fund operations. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. However, the negative net cash position after debt is a red flag for potential liquidity stress in the event of a funding disruption. No recent events, such as earnings calls, regulatory filings, or major business announcements, are disclosed in the available data. This lack of transparency or communication may limit investor confidence and could impact the company's ability to attract capital or partnerships in the near term.

30-day price · NANEXA-0.08 (-2.0%)
Low$3.25High$4.11Close$3.60As of9 May, 00:00 UTC
Profile
CompanyNanexa AB
TickerNANEXA.ST
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Nanexa AB is a medical equipment and supplies company that operates within the healthcare services and equipment sector, primarily generating revenue through the development, production, and distribution of medical devices and related products.

Classification. Nanexa AB is classified under the industry "Medical Equipment, Supplies & Distribution" within the broader Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Nanexa AB's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative approach to leverage. However, the company's liquidity position is assessed as medium, with a current ratio of 1.51, suggesting it has sufficient short-term assets to cover its liabilities but with limited buffer for unexpected cash flow disruptions. The company's free cash flow is negative at -23.6 million SEK, and operating cash flow is also negative at -1.5 million SEK, signaling ongoing cash burn despite a net cash position that turns negative after subtracting total debt. Profitability metrics for Nanexa AB are weak, with a return on equity (ROE) of -11.22% and a return on assets (ROA) of -8.24%. These figures are below the typical thresholds for healthy performance in the medical equipment and supplies industry, where ROE and ROA are key indicators of operational efficiency and capital utilization. The company reported a net loss of 11.4 million SEK and an operating loss of 8.8 million SEK, further underscoring the challenges in achieving profitability. The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no material geographic diversification provided in the available data. This lack of segment or geographic diversification increases exposure to sector-specific risks and limits the ability to offset performance shortfalls in one area with gains in another. Nanexa AB's growth trajectory is currently constrained, with no specific revenue growth projections provided in the outlook. The company's capital expenditures of 24.7 million SEK reflect ongoing investment in infrastructure or expansion, but the negative free cash flow suggests these investments are not yet generating sufficient returns. The absence of a clear growth strategy or revenue acceleration in the near term raises concerns about the company's ability to scale profitably. The risk assessment highlights liquidity as a medium concern, with the company's negative free cash flow and operating cash flow indicating a reliance on external financing or asset sales to fund operations. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. However, the negative net cash position after debt is a red flag for potential liquidity stress in the event of a funding disruption. No recent events, such as earnings calls, regulatory filings, or major business announcements, are disclosed in the available data. This lack of transparency or communication may limit investor confidence and could impact the company's ability to attract capital or partnerships in the near term.
Key takeaways
  • Nanexa AB is operating at a net loss with negative free and operating cash flows, indicating ongoing financial stress.
  • The company's conservative debt structure is offset by weak profitability and liquidity concerns.
  • There is no disclosed geographic or segment diversification, increasing exposure to sector-specific risks.
  • Capital expenditures are significant, but the company has not yet achieved positive returns on these investments.
  • The absence of recent business or financial events limits visibility into the company's strategic direction.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$36.1M
Gross profit$31.1M
Operating income-$8.8M
Net income-$11.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$1.5M
CapEx-$24.7M
Free cash flow-$23.6M
Total assets$138.1M
Total liabilities$36.6M
Total equity$101.5M
Cash & equivalents
Long-term debt$2.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$101.5M
Net cash-$2.2M
Current ratio1.5
Debt/Equity0.0
ROA-8.2%
ROE-11.2%
Cash conversion13.0%
CapEx/Revenue-68.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricNANEXAActivity
Op margin-24.3%3.9% medp25 -31.3% · p75 14.4%below median
Net margin-31.5%2.4% medp25 -30.5% · p75 11.1%bottom quartile
Gross margin86.0%46.7% medp25 28.2% · p75 63.1%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-68.5%-4.8% medp25 -11.6% · p75 -2.4%bottom quartile
Debt / equity2.0%17.9% medp25 2.7% · p75 52.2%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 16:35 UTC#64a1a2cc
Market quoteclose SEK 3.60 · shares 0.16B diluted
no public URL
2026-05-10 05:42 UTC#2a4ae81e
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 16:56 UTCJob: aebf8bf8